Researchers evaluate efficacy of therapy regimens for neglected tropical disease, Visceral Leishmaniasis (VL). Meta-analysis of 131 studies quantifies proportion of relapses observed at and beyond 6-months. Proportion of relapses after recommended drug regimen ranges from 0.5 to 4.5% in the Indian sub-continent. Longer follow-up may be warranted. Therapeutic interventions can significantly reduce mortality. Higher doses of L-AmB may be more effective in preventing relapse. Combination therapy reduces treatment duration and overall burden to health systems. Prompt changes in treatment recommendation and regular drug efficacy surveillance are important.
